U.S. Equine Healthcare Market Size, Share & Forecast 2026–2032

ID: MR-11324 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Equine Healthcare
  • ✓Market Size 2024: USD 1.72 billion
  • ✓Market Size 2032: USD 2.62 billion
  • ✓CAGR: 5.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Racing Rules Reshape Demand: The Horseracing Integrity and Safety Authority's uniform medication rules push Kentucky and New York trainers toward FDA-approved products with validated withdrawal windows. This shift lifts demand for laboratory-verified diagnostics and certified supply chains.
FINDING 02
Branded Products Hold Margins: Generic entry will not compress equine drug prices as it did in human pharmaceuticals. Racing compliance, not patent status, anchors pricing because trainers pay premiums for documented withdrawal data. Branded anti-infectives from Zoetis will hold margins through 2030.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Accredited Supply Now: Distributors and investors should secure USDA-licensed vaccine and FDA-approved anti-infective supply agreements before the first quarter of 2027, when ADUFA V performance commitments reshape approval queues. Prioritize racing-jurisdiction certified products to lock in compliance-driven margins.

Equine Health in the U.S.: Market Overview

The U.S. equine healthcare market generated an estimated USD 1.72 billion in 2024 and sits within a broader animal health sector dominated by federally regulated pharmaceuticals and biologics. Government has shaped its current form most directly through the Federal Food, Drug, and Cosmetic Act, which FDA's Center for Veterinary Medicine enforces for equine drugs, and the Virus-Serum-Toxin Act of 1913, under which USDA's Center for Veterinary Biologics licenses equine vaccines.

Public authority dominates disease control: USDA APHIS oversees Equine Infectious Anemia testing requirements for interstate movement, while state veterinarians impose entry rules. Private industry leads commercial demand, with Zoetis, Boehringer Ingelheim and Elanco supplying most branded anti-infectives, vaccines and parasiticides. Racing bodies such as the Jockey Club and the Kentucky Horse Racing Commission shape testing volumes, and veterinary practices dispense most prescription products.

Policy-Driven Growth in U.S. Equine Health

Three mechanisms drive demand. First, the Horseracing Integrity and Safety Act of 2020, enacted through the National Defense Authorization Act for Fiscal Year 2021 and enforced by the Horseracing Integrity and Safety Authority since July 2022, requires uniform Anti-Doping and Medication Control testing across covered racetracks. This translates directly into higher demand for laboratory analysis and FDA-approved treatments with documented withdrawal periods.

Second, the Veterinary Feed Directive and FDA Guidance for Industry #263 moved medically important antimicrobials to prescription status on June 11, 2023, routing equine antibiotic purchases through licensed veterinarians and increasing diagnostic-linked prescribing. Third, state Equine Infectious Anemia requirements built on USDA APHIS rules mandate negative Coggins test results for interstate movement, sustaining steady testing volumes across breeding and sport horse populations.

Regulatory Barriers and Compliance Costs

FDA's Center for Veterinary Medicine reviews new equine drug applications under the Animal Drug User Fee Act, reauthorized as ADUFA V for fiscal years 2024 through 2028. Sponsors pay application fees that set the minimum commercial viability for narrow equine indications. USDA's Center for Veterinary Biologics requires establishment and product licences under the Virus-Serum-Toxin Act, with each vaccine serial tested before release, adding months to launch timelines.

Racing compliance adds a second cost layer. Under the Horseracing Integrity and Safety Authority's Prohibited Substances List, trainers face strict withdrawal windows and laboratory costs at accredited testing facilities. Section 301 tariffs on Chinese-origin active pharmaceutical ingredients raise input costs for generic anthelmintics and antibiotics. Interstate shipment also requires health certificates from accredited veterinarians, adding per-animal fees and delays at state borders.

Policy-Created Opportunities in the United States

USDA's National Institute of Food and Agriculture administers the Animal Health and Disease Research Program, which funds equine disease research and creates demand for diagnostic partners. University veterinary colleges, including Cornell and Colorado State, receive grants for equine infectious disease work. Research outputs from these programmes generate follow-on procurement for validated assays and vaccine trials, opening supply opportunities for specialist laboratories.

The Horseracing Integrity and Safety Authority's accreditation requirements for testing laboratories and sample collection agencies open demand for certified diagnostic services. Providers holding ISO/IEC 17025 accreditation gain preferred access to racing jurisdictions. Racing participants must document administered medications, which creates demand for electronic medication-tracking platforms integrated with racing jurisdiction databases.

Market at a Glance

MetricValue
Market Size 2024USD 1.72 billion
Market Size 2032USD 2.62 billion
Growth Rate (CAGR)5.4%
Most Critical Decision FactorCompliance with HISA medication rules and FDA approval status
Largest RegionSouth (Kentucky, Florida, Texas)
Competitive StructureConcentrated among multinationals; fragmented veterinary distribution

Leading Market Participants

  • Zoetis
  • Merck Animal Health
  • Boehringer Ingelheim Animal Health
  • Elanco Animal Health
  • Ceva Santé Animale
  • Dechra Pharmaceuticals
  • Vetoquinol USA
  • Neogen Corporation
  • Covetrus
  • Mars Veterinary Health

Regulatory and Policy Environment

The primary framework comprises the Federal Food, Drug, and Cosmetic Act, administered by FDA's Center for Veterinary Medicine, and the Virus-Serum-Toxin Act, administered by USDA's Center for Veterinary Biologics. The Animal Medicinal Drug Use Clarification Act of 1994 permits veterinarians to prescribe approved drugs off-label under defined conditions. The Horse Protection Act of 1970 is enforced by USDA APHIS against soring in show and sale horses. Compliance requires approved labelling, establishment licensing and documented extra-label records.

Upcoming changes include the scheduled expiry of ADUFA V on September 30, 2028, with FDA and industry negotiating ADUFA VI during 2027. The Horseracing Integrity and Safety Authority continues to update its Uniform Rules annually. Compared with the European Union, whose Regulation (EU) 2019/6 on veterinary medicinal products harmonises authorisation across member states, the U.S. system remains fragmented between federal and state rules. Canada's Health Canada Veterinary Drugs Directorate reviews equine products through a single national submission route.

Long-Term Policy Outlook for U.S. Equine Health

By 2032, the Horseracing Integrity and Safety Authority will extend uniform medication standards deeper into covered racing categories, tightening demand for certified testing and approved treatments in states that currently operate separate rules. State racing commissions will align withdrawal schedules with national Uniform Rules, reducing compliance variation and favouring suppliers with complete withdrawal data packages.

ADUFA VI negotiations during 2027 will determine fee structures from fiscal 2029 onward, shaping how quickly FDA approves new equine indications. Continued tariff exposure on Chinese-origin active ingredients will push manufacturers such as Zoetis and Elanco toward domestic and Indian API sourcing. This shift will reshape generic cost curves and raise pricing for mid-tier anti-infectives.

Frequently Asked Questions

FDA's Center for Veterinary Medicine approves equine drugs under the Federal Food, Drug, and Cosmetic Act. Sponsors pay application fees under ADUFA V for fiscal years 2024 through 2028.
Trainers at covered racetracks must comply with the Anti-Doping and Medication Control Program enforced by the Horseracing Integrity and Safety Authority. Violations trigger sanctions based on the Prohibited Substances List and withdrawal rules.
Yes, USDA's Center for Veterinary Biologics licenses equine vaccines under the Virus-Serum-Toxin Act of 1913. Each vaccine serial is tested before release to market.
Medically important antimicrobials have required veterinary oversight since June 11, 2023, under FDA Guidance for Industry #263. Purchases now run through licensed veterinarians rather than over the counter.
Negative Equine Infectious Anemia test results are required for interstate movement under USDA APHIS rules and state entry requirements. Horses without current test documentation face quarantine or rejection at state borders.

Market Segmentation

By Product Type
  • Vaccines
  • Anti-infectives
  • Parasiticides
  • Diagnostics
By End User
  • Racing Thoroughbreds
  • Sport Horses
  • Breeding Farms
  • Companion Horses
By Distribution Channel
  • Veterinary Practices
  • Distributors
  • Online Pharmacies
  • Farm Supply Retail

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Equine Health - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Vaccines
4.2 Anti-infectives
4.3 Parasiticides
4.4 Diagnostics
4.5 Others
Chapter 05 End User Insights
5.1 Racing Thoroughbreds
5.2 Sport Horses
5.3 Breeding Farms
5.4 Companion Horses
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Veterinary Practices
6.2 Distributors
6.3 Online Pharmacies
6.4 Farm Supply Retail
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Zoetis
7.2.2 Merck Animal Health
7.2.3 Boehringer Ingelheim Animal Health
7.2.4 Elanco Animal Health
7.2.5 Ceva Santé Animale
7.2.6 Dechra Pharmaceuticals
7.2.7 Vetoquinol USA
7.2.8 Neogen Corporation
7.2.9 Covetrus
7.2.10 Mars Veterinary Health
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.